Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • Chapter 5 - Prescribing in Pregnancy

  • from Part 2 - Prescribing for Patient Groups
  • Edited by Hugh Montgomery, Robert Shulman, Mayur Murali
  • Book: Surviving Prescribing
  • Published online: 08 June 2020
  • Print publication: 25 June 2020, pp 25-30

  • Summary

    The thalidomide disaster of 1958 and later isotretinoin from 1995 showed that drugs do reach the foetus and can cause harm. Even now, of the babies born with a recognised birth defect, drugs are implicated in 1–2%. As a result, there is a perception that any drug at any time in pregnancy could cause harm; however, this is not the case! It’s important to consider the benefit to the mother, the risk to the foetus and the form of administration. This chapter discusses some of the most common drug classes and whether and when they can be safely used in pregnancy.